VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IMVT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HomeStocksIMVTInstitutional Holders

IMVT logoImmunovant, Inc. (IMVT) Institutional Ownership

Q2 2026 13F Data|Updated 2026-11-18

✨

Institutional ownership decreased this quarter (-1.08 pp), while top 10 holders maintain a highly concentrated 60.4% of value.

Institutional Ownership
Can exceed 100% due to securities lending, short interest, and reporting timing differences.
54.4%$4.2B total value · ▼ 1.08 pp vs prior quarter
Smart Money Score
Based on ownership concentration, fund quality, buying/selling activity, ownership indicators, and institutional trend.
42 / 100Neutral
Institutions & Flow227 holders+11 net flow (+34 / -23)

AI Insights & Key Takeaways

  • Positive Institutional Flow (+11)
  • Susquehanna International Group, Llp maintains a significant position
  • Top 10 holders control 60.4% of institutional value
  • No Insider Signal

Top Institutional Holders of IMVT

Ranked by reported Q2 2026 13F market value

Top 10 Holders
60.4%
Top 25 Holders
87.4%

Share of total reported institutional value in IMVT held by the largest 10 / 25 filers.

#InstitutionShares HeldMarket ValueQoQ ChangeOwnership %% of Fund
1FMR LLC16.2M$623.7M-4.5%7.842%0.03%
2Deep Track Capital, LP9.3M$359.9M-19.0%4.526%5.24%
3BlackRock, Inc.7.2M$276.7M+9.2%3.479%0.00%

Quarterly Institutional Activity

Filings activity in IMVT during Q2 2026, grouped by how each filer changed its position.

OverviewNew Buyers34Added To162Trimmed23Exited23
  • ARMISTICE CAPITAL, LLC$113.1M
  • Alpine Global Management, LLC$53.0M

IMVT Institutional Ownership by Quarter

8 quarters of 13F filings · Δ columns show change vs prior quarter

QuarterInst. HoldersΔ HoldersOwnership %Δ OwnershipTotal 13F ValueΔ Value
Q2 2026227+5.6%54.43%1.08 pp$4.15B+53%
Q1 2026215+9.1%55.51%+3.65 pp$2.71B+2.6%
Q4 2025197+6.5%51.86%3.38 pp$2.64B+81%
Q3 2025185+11%55.24%0.78 pp$1.46B+3.5%
Q2 202516713%56.02%+0.16 pp$1.41B6.2%
Q1 2025192+4.9%

How IMVT Compares to Peers

Institutional ownership and quarterly buying activity across the largest Immunology Biotech peers.

TickerCompanyMarket CapInst. OwnershipHoldersNet Buyers − Sellers
LKFTLakefront Biotherapeutics N.V.$2.19B49.6%79-12
YARWYarrow Bioscience Inc$145M1.2%47+2
RKTORocket One Inc.$9M7.9%22+3

IMVT — Frequently Asked Questions

Quick answers to the most common questions about buying IMVT stock.

What percentage of IMVT is owned by institutions?

Based on Q2 2026 13F filings, institutional ownership of Immunovant, Inc. stands at 54.4%, held across 227 reporting institutions.

Who is the largest institutional holder of IMVT?

FMR LLC is the largest reported institutional holder of IMVT, with approximately 16,186,469 shares worth $0.62B as of Q2 2026.

Is IMVT a hedge fund favorite?

Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of IMVT, including SUSQUEHANNA INTERNATIONAL GROUP, LLP.

What is IMVT's Smart Money Score?

Our composite Smart Money Score for IMVT is 42 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.

How many institutions bought IMVT this quarter?

34 institutions opened new positions in IMVT during Q2 2026, while 23 fully exited. 162 added to existing positions and 23 trimmed.

4
FARALLON CAPITAL MANAGEMENT, L.L.C.
5.8M
$223.7M
+275.5%
2.813%
0.97%
5BAKER BROS. ADVISORS LP5.4M$209.4M-0.4%2.633%1.05%
6STATE STREET CORP4.6M$177.9M+1.7%2.237%0.00%
7MORGAN STANLEY4.5M$174.7M+17.0%2.197%0.01%
8TCG Crossover Management, LLC4.5M$171.8M0.0%2.160%4.13%
9VANGUARD PORTFOLIO MANAGEMENT LLC3.9M$150.7M+5.5%1.895%0.01%
10VANGUARD CAPITAL MANAGEMENT LLC3.6M$140.2M+0.5%1.763%0.00%
11JENNISON ASSOCIATES LLC3.3M$127.5M+3.5%1.604%0.08%
12RTW INVESTMENTS, LP3.2M$122.4M0.0%1.540%1.05%
13Two Seas Capital LP3.1M$121.3M-1.7%1.525%2.40%
14ARMISTICE CAPITAL, LLC2.9M$113.1M-46.3%1.422%1.38%
15ADAR1 Capital Management, LLC2.3M$89.8M-13.0%1.129%4.11%
16GEODE CAPITAL MANAGEMENT, LLC2.2M$86.1M+6.8%1.083%0.00%
17Woodline Partners LP2.0M$76.1M0.0%0.957%0.24%
18GOLDMAN SACHS GROUP INC1.8M$67.5M-1.9%0.848%0.01%
19Alpine Global Management, LLC1.4M$53.0M-47.9%0.666%8.61%
20SUSQUEHANNA INTERNATIONAL GROUP, LLP1.4M$52.7M+12.4%0.663%0.00%
21PERCEPTIVE ADVISORS LLC1.4M$52.3M-15.0%0.658%0.79%
22D. E. Shaw & Co., Inc.1.2M$47.8M—0.601%0.02%
23BANK OF AMERICA CORP /DE/1.2M$45.5M+32.2%0.572%0.00%
24Aberdeen Group plc857K$33.0M-26.2%0.415%0.05%
25NORTHERN TRUST CORP794K$30.6M+18.0%0.385%0.00%

denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in IMVT — a direct measure of their conviction.

Logos Global Management LP
$25.6M
  • STEMPOINT CAPITAL LP$10.7M
  • SUPERSTRING CAPITAL MANAGEMENT LP$8.0M
  • XTX Topco Ltd$3.5M
  • TD ASSET MANAGEMENT INC$2.9M
  • Rafferty Asset Management, LLC$2.8M
  • PROFUND ADVISORS LLC$1.4M
  • Assenagon Asset Management S.A.$639K
  • Bridgefront Capital, LLC$543K
  • Quinn Opportunity Partners LLC$501K
  • 55.86%
    +1.21 pp
    $1.51B
    18%
    Q4 2024183+1.7%54.65%+0.72 pp$1.83B13%
    Q3 2024180—53.93%—$2.10B—

    Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.

    How is institutional ownership of IMVT changing?

    IMVT institutional ownership fell by 1.08 percentage points quarter-over-quarter, with a net change of +12 holders.

    How concentrated is IMVT ownership among the top holders?

    The top 10 institutions account for 60.4% of all reported 13F value in IMVT, and the top 25 account for 87.4%.

    How does IMVT compare to Immunology Biotech on institutional ownership?

    Across the largest Immunology Biotech peers, institutional ownership levels are: LKFT (49.6%), YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.

    Where does this IMVT institutional ownership data come from?

    All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.

    IMVTImmunovant, Inc.
    $33.17$6.8B
    Overview & Tools
    OverviewChart Terminal ↗Visualize
    Valuation & Forecasts
    Valuation ModelsEstimatesDCF Model
    Price & Analyst Data
    Analyst TargetsPrice History
    Financial Statements
    Income StatementBalance SheetCash FlowRatios & Margins
    Performance
    P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
    Discovery & Screens
    Live BreakoutsStock ScreenerOwnership